Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna chief executive officer Stéphane Bancel steps down as chief commercial officer, with president Stephen Hoge assuming ...

Moderna stock rises as Q3 revenue beats estimates at $1.83 billion, driven by strong U.S. COVID-19 vaccine sales. EPS of $0.03 exceeds expectations.

dosages of the Pfizer-BioNTech vaccine. Other vaccines (such as Moderna) were excluded from analyses. The final older (12-17 ...

Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial ...

Arbutus Biopharma Corp (ABUS) showcases significant progress in hepatitis B treatment and maintains a robust cash runway into ...

It’s too early to know if Robert F. Kennedy Jr. will have an important healthcare role in a second Trump administration, but ...

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD - The Liver Meeting ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Market Reaction: Big Pharma's vaccine names dipped on Wednesday with Moderna, Inc. (NASDAQ:MRNA) ending the day down 2.78%, ...

Both the Moderna and Pfizer/BioNTech actions are being heard in a Delaware district court. The lawsuits contribute to an ongoing bun fight between various parties involved in mRNA vaccines ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found to be unrelated ...